Evidence map›Paper›PMID 34520898›Full record

ReviewBone2021

Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

J I Aguirre, E J Castillo, D B Kimmel

Abstract readReview
In one paragraph

Review in Bone, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Mesenchymal Stem Cells in Socket Healing and MRONJ.Orthodontics & craniofacial research · 2025
    Review
  5. Role of microRNA in Diabetic Osteoporosis.Molecular biotechnology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J I AguirreDepartment of Physiological Sciences, University of Florida (UF), Gainesville, FL, United States of America. Electronic address: aguirrej@ufl.edu.
E J CastilloDepartment of Physiological Sciences, University of Florida (UF), Gainesville, FL, United States of America. Electronic address: evelynjcastillo@ufl.edu.
D B KimmelDepartment of Physiological Sciences, University of Florida (UF), Gainesville, FL, United States of America.

Funding

Role of Periodontitis in Osteonecrosis of the Jaw Pathophysiology in Rice RatsR01DE023783 · NIDCR · UNIVERSITY OF FLORIDA · PI AGUIRRE, JOSE IGNACIO · 2014 to 2018
$1.7M
NIDCR NIH HHS R01 DE023783
6 · The paper itself

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event affecting patients with cancer and patients with osteoporosis who have been treated with powerful antiresorptives (pARs) or angiogenesis inhibitors (AgIs). pARs, including nitrogen-containing bisphosphonates (N-BPs; e.g., zoledronic acid, alendronate) and anti-RANKL antibodies (e.g., denosumab), are used to manage bone metastases in patients with cancer or to prevent fragility fractures in patients with osteoporosis. Though significant advances have been made in understanding MRONJ, its pathophysiology is still not fully elucidated. Multiple species have been used in preclinical MRONJ research, including the rat, mouse, rice rat, rabbit, dog, sheep, and pig. Animal research has contributed immensely to advancing the MRONJ field, particularly, but not limited to, in developing models and investigating risk factors that were first observed in humans. MRONJ models have been developed using clinically relevant doses of systemic risk factors, like N-BPs, anti-RANKL antibodies, or AgIs. Specific local oral risk factors first noted in humans, including tooth extraction and inflammatory dental disease (e.g., periodontitis, periapical infection, etc.), were then added. Research in rodents, particularly the rat, and, to some extent, the mouse, across multiple laboratories, has contributed to establishing multiple relevant and complementary preclinical models. Models in larger species produced accurate clinical and histopathologic outcomes suggesting a potential role for confirming specific crucial findings from rodent research. We view the current state of animal models for MRONJ as good. The rodent models are now reliable enough to produce large numbers of MRONJ cases that could be applied in experiments testing treatment modalities. The course of MRONJ, including stage 0 MRONJ, is characterized well enough that basic studies of the molecular or enzyme-level findings in different MRONJ stages are possible. This review provides a current overview of the existing models of MRONJ, their more significant features and findings, and important instances of their application in preclinical research.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsBone NeoplasmsDisease Models, AnimalAnimalsDenosumabDiphosphonatesDogsHumansMiceRabbitsRatsSheepSwineBone Density Conservation AgentsDenosumabDiphosphonatesAnimal modelsBisphosphonatesBRONJMRONJONJPreclinical studiesRANKL-inhibitors

Identifiers

PMID34520898
PMCPMC8743993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.